Business Description
Immutep Limited is an Australian biotechnology company focused on developing treatments for cancer and autoimmune diseases, using a mechanism that activates the immune system through a protein called LAG-3. Its leading therapy, eftilagimod alfa, is being tested across multiple clinical trials covering a range of cancers including lung, head and neck, breast, and bladder cancers, as well as soft tissue sarcoma. The company also has early-stage programs targeting autoimmune conditions. Founded in 1987 and headquartered in Sydney, Immutep works alongside partners such as Merck & Co., Novartis, EOC Pharma, and Labcorp to advance its research pipeline.
